Cargando…

Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas

Background. Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results. Patients and Methods. Analysis of consecutive patients with neuroendocrine carc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olsen, Ingrid H., Sørensen, Jens B., Federspiel, Birgitte, Kjaer, Andreas, Hansen, Carsten P., Knigge, Ulrich, Langer, Seppo W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Scientific World Journal 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432352/ https://www.ncbi.nlm.nih.gov/pubmed/22973169 http://dx.doi.org/10.1100/2012/170496

Ejemplares similares

Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas
por: Olsen, Ingrid Holst, et al.
Publicado: (2014)

Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review
por: Ilett, Emma Elizabeth, et al.
Publicado: (2015)

P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms
por: Nielsen, Kirstine, et al.
Publicado: (2020)

Incidence, Clinical Presentation and Trends in Indication for Diagnostic Work-Up of Small Intestinal and Pancreatic Neuroendocrine Tumors
por: Stensbøl, Anna Bryan, et al.
Publicado: (2021)

Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors
por: Baekdal, Jonas, et al.
Publicado: (2020)

Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases
por: Langer, Seppo W., et al.
Publicado: (2015)

Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 83 Patients
por: Olsen, Ingrid Holst, et al.
Publicado: (2015)

Somatostatin Analogue Treatment Primarily Induce miRNA Expression Changes and Up-Regulates Growth Inhibitory miR-7 and miR-148a in Neuroendocrine Cells
por: Døssing, Kristina B. V., et al.
Publicado: (2018)

Gene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular Proliferation
por: Binderup, Tina, et al.
Publicado: (2013)

Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors
por: Kjaer, Andreas, et al.
Publicado: (2015)

Down-Regulation of miR-129-5p and the let-7 Family in Neuroendocrine Tumors and Metastases Leads to Up-Regulation of Their Targets Egr1, G3bp1, Hmga2 and Bach1
por: Døssing, Kristina B. V., et al.
Publicado: (2014)

Initial Experience with (64)Cu-DOTATATE Digital PET of Patients with Neuroendocrine Neoplasms: Comparison with Analog PET
por: Loft, Mathias, et al.
Publicado: (2021)

Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
por: Tafuto, Salvatore, et al.
Publicado: (2019)

PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
por: Ali, Abir Salwa, et al.
Publicado: (2020)

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
por: De Divitiis, C., et al.
Publicado: (2016)

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma
por: Ali, Abir Salwa, et al.
Publicado: (2017)

Alternative Polyadenylation of Tumor Suppressor Genes in Small Intestinal Neuroendocrine Tumors
por: Rehfeld, Anders, et al.
Publicado: (2014)

S-1 plus temozolomide as second-line treatment for neuroendocrine carcinoma of the breast: A case report
por: Wang, Xin, et al.
Publicado: (2021)

A convolutional neural network for total tumor segmentation in [(64)Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms
por: Carlsen, Esben Andreas, et al.
Publicado: (2022)

Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma
por: Couronne, Thomas, et al.
Publicado: (2020)

Hitherto unseen survival in an ALK‐positive‐patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine
por: Risum, Signe, et al.
Publicado: (2017)

(18)F-FDG and (18)F-FLT-PET Imaging for Monitoring Everolimus Effect on Tumor-Growth in Neuroendocrine Tumors: Studies in Human Tumor Xenografts in Mice
por: Bardram Johnbeck, Camilla, et al.
Publicado: (2014)

Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial
por: Zeyen, Thomas, et al.
Publicado: (2022)

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
por: Ko, J J, et al.
Publicado: (2014)

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary
por: Chauhan, Aman, et al.
Publicado: (2018)

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
por: Ray-Coquard, I, et al.
Publicado: (2013)

Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor
por: Wu, Yin, et al.
Publicado: (2013)

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
por: Ali, Abir Salwa, et al.
Publicado: (2018)

Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature
por: Tena, Isabel, et al.
Publicado: (2018)

Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
por: Devata, Sumana, et al.
Publicado: (2012)

Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)
por: Thomas, Katharine, et al.
Publicado: (2020)

Treatment of ampullary neuroendocrine tumor by Capecitabine (Xeloda®) and Temozolomide (Temodal®)
por: Noorali, Sima, et al.
Publicado: (2021)

Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors
por: Al-Toubah, Taymeyah, et al.
Publicado: (2022)

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
por: Hottinger, A F, et al.
Publicado: (2014)

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials
por: Ferretti, G, et al.
Publicado: (2006)

Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors
por: Kotteas, Elias A, et al.
Publicado: (2016)

Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma
por: Kobayashi, Noritoshi, et al.
Publicado: (2021)

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
por: Owen, Dwight H., et al.
Publicado: (2023)

Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain
por: Lamas, Cristina, et al.
Publicado: (2023)

Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma
por: Cosentini, Deborah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1le1766bscr0oi7759b3ogpfen